We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+89.28%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$499M
AUM Growth
+$188M
Cap. Flow
+$206M
Cap. Flow %
41.36%
Top 10 Hldgs %
50.9%
Holding
101
New
48
Increased
19
Reduced
18
Closed
14

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$44.5M
2
DNLI icon
Denali Therapeutics
DNLI
+$14.8M
3
BHVN icon
Biohaven
BHVN
+$12.3M
4
WVE icon
Wave Life Sciences
WVE
+$9.79M
5
ARGX icon
argenx
ARGX
+$8.22M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$16.6M
2
MRUS
Merus
MRUS
+$14M
3
ACLX
Arcellx
ACLX
+$13.7M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$13.2M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.58%
2 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XFOR icon
51
X4 Pharmaceuticals
XFOR
$360M
$1.9M 0.38%
+555,411
New +$1.43M
PEPG icon
52
PepGen
PEPG
$156M
$1.8M 0.36%
+389,189
New +$627K
ASMB icon
53
Assembly Biosciences
ASMB
$531M
$1.69M 0.34%
+66,130
New +$1.45M
DNTH icon
54
Dianthus Therapeutics
DNTH
$5.77B
$1.63M 0.33%
+41,382
New +$1.06M
PCSC
55
Perceptive Capital Solutions
PCSC
$123M
$1.59M 0.32%
150,000
– –
TARA icon
56
Protara Therapeutics
TARA
$230M
$1.58M 0.32%
363,666
-780,011
-68% -$2.53M
CMPS
57
Compass Pathways
CMPS
$1.67B
$1.58M 0.32%
+275,620
New +$1.24M
PYXS icon
58
Pyxis Oncology
PYXS
$150M
$1.53M 0.31%
+689,538
New +$993K
MBX
59
MBX Biosciences
MBX
$2.99B
$1.31M 0.26%
75,000
-66,021
-47% -$883K
BHVN icon
60
CALL
Biohaven
BHVN
$2.32B
$1.19M 0.24%
+480,000
New +$6.99M
ADCT icon
61
ADC Therapeutics
ADCT
$172M
$1.13M 0.23%
283,286
– –
ACLX
62
DELISTED
Arcellx
ACLX
$934K 0.19%
11,376
-190,076
-94% -$13.7M
ABUS icon
63
Arbutus Biopharma
ABUS
$901M
$932K 0.19%
+205,388
New +$754K
DFTX
64
Definium Therapeutics
DFTX
$5.88B
$906K 0.18%
76,875
-13,977
-15% -$130K
CNTA
65
CALL
DELISTED
Centessa Pharmaceuticals
CNTA
$906K 0.18%
+172,500
New +$3.07M
ENTA icon
66
Enanta Pharmaceuticals
ENTA
$400M
$900K 0.18%
+75,194
New +$601K
ZBIO
67
Zenas BioPharma
ZBIO
$1.86B
$860K 0.17%
+38,742
New +$631K
WHWK
68
Whitehawk Therapeutics
WHWK
$192M
$806K 0.16%
+424,082
New +$780K
XBI icon
69
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$725K 0.15%
+1,490,100
New +$134M
CRVS icon
70
Corvus Pharmaceuticals
CRVS
$1.25B
$711K 0.14%
+96,439
New +$494K
KALV
71
DELISTED
KalVista Pharmaceuticals
KALV
$691K 0.14%
56,770
-330,020
-85% -$4.56M
MGTX icon
72
MeiraGTx Holdings
MGTX
$1.15B
$674K 0.14%
+81,858
New +$647K
TERN
73
DELISTED
Terns Pharmaceuticals
TERN
$673K 0.13%
+89,617
New +$572K
ARCT icon
74
Arcturus Therapeutics
ARCT
$172M
$656K 0.13%
+35,606
New +$572K
VTYX
75
DELISTED
Ventyx Biosciences
VTYX
$521K 0.1%
+167,470
New +$444K
1 2
3
4 5

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Stempoint Capital held 101 positions worth $499M, up 60% from $312M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital deployed $206M of net new capital in Q3 2025, opening 48 new positions and adding to 19 existing holdings. Its largest new stake was argenx: 12,465 shares worth $9.19M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Madrigal Pharmaceuticals, an estimated $16.6M trimmed.

  • Stempoint Capital's largest Q3 2025 buy was argenx: 12,465 shares worth $9.19M.
  • Stempoint Capital added most to Roivant Sciences in Q3 2025, an estimated $44.5M increase.
  • Stempoint Capital's biggest Q3 2025 reduction was Madrigal Pharmaceuticals, cutting an estimated $16.6M.
  • Stempoint Capital fully exited Merus in Q3 2025, selling an estimated $14M.
  • Stempoint Capital's ten largest holdings make up 51% of its $499M portfolio in Q3 2025.
  • Stempoint Capital opened 48 new positions and closed 14 in Q3 2025.
  • Stempoint Capital's portfolio value rose 60% quarter-over-quarter to $499M.

Based on Stempoint Capital's 13F filing for Q3 2025, filed 14 Nov 2025.